Histrelin: In advanced prostate cancer

Drugs

Volumn 70, Issue 5, 2010, Pages 623-630

  Deeks, Emma D ^a  

^a Wolters Kluwer   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTRELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; AREA UNDER THE CURVE; CANCER PALLIATIVE THERAPY; CANCER STAGING; CASTRATION; CLINICAL TRIAL; CONSTIPATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; ERYTHEMA; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPLANT; INFECTION; INFLAMMATION; INSOMNIA; KIDNEY DISEASE; LIBIDO DISORDER; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; PAIN; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN BRUISING; SWELLING; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77949956337     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204800-000000000-00000     Document Type: Review

References (24)

1. American Cancer Society®. Global cancer facts and figures 2007 [online]. Available from URL: http://www.cancer.org/downloads/STT/Global-Facts- and-Figures-2007-rev2.pdf [Accessed 2009 Dec 16]
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009 Jul-Aug 31; 59 (4): 225-249
3. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007 Jun; 177 (6): 2106-2131
4. Horwich A, Parker C, Kataja V. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008 May; 19 Suppl. 2: ii45-6
5. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007 Apr 20; 25 (12): 1596-1605
6. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment [online]. Available from URL http://www.nice.org.uk/ nicemedia/pdf/CG58FullGuideline.pdf [Accessed 2009 Dec 9]
7. National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology™ prostate cancer, V.2.2009 [online]. Available from URL: http://www.nccn.org [Accessed 2009 Dec 9]
8. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008 Jan; 53 (1): 68-80
9. Kintzel PE, Chase SL, Schultz LM, et al. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008 Dec; 28 (12): 1511-22.
10. Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009; 12 (4): 333-338
11. van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008 Jun; 71 (6): 1001-1006
12. Schlegel P. A review of the pharmacokinetic and pharma-cological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer. BJU Int 2009 Mar; 103 Suppl. 2: 7-13
13. Hall MC, Fritzsch RJ, Sagalowsky AI, et al. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999 May; 53 (5): 898-903
14. Oefelein MG. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol 1998 Nov; 160 (5): 1685-1688
15. Food and Drug Administration. Vantas™ (histrelin implant): US prescribing information [online]. Available from URL http://www.accessdata.fda. gov/drugsatfda-docs/label/2004/21732lbl.pdf [Accessed 2009 Dec 4]
16. Orion Pharma (UK) Limited. Vantas 50mg implant: UK summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2009 Dec 4]
17. Barradell LB, McTavish D. Histrelin: a review of its pharmacological properties and therapeutic role in central precocious puberty. Drugs 1993; 45 (4): 570-588
18. Schlegel PN, Kuzma P, Frick J, et al. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology 2001 Oct; 58 (4): 578-582
19. Schlegel PN. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol 2006 Apr; 175 (4): 1353-1358
20. Doelle GC, Evans RM, Alexander AN, et al. Single dose responses to the gonadotropin-releasing hormone agonist analogue [(imBz 1)-D-His6,Pro9-NEt]GnRH. Horm Metab Res 1986 Mar; 18 (3): 201-202
21. DeFazio J, Lu JKH, Vale W, et al. Effects of the (imBz1)D-His6, Des-Gly analog of GnRH on gonadotropin and estradiol secretion in normal women. Endocr Res 1984; 10 (2): 163-170
22. Dineen MK, Tierney DS, Kuzma P, et al. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. J Clin Pharmacol 2005 Nov; 45 (11): 1245-1249
23. Chertin B, Spitz IM, Lindenberg T, et al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol 2000 Mar; 163 (3): 838-844
24. Fridmans A, Chertin B, Koulikov D, et al. Reversibility of androgen deprivation therapy in patients with prostate cancer. J Urol 2005 Mar; 173 (3): 784-9